Agreement dated as of December 31, 1993, between Medi-Ject Corporation, 1840 Berkshire Lane,
Minneapolis, Minnesota, USA 55441 ("Medi-Ject"), and Ferring N.V., Pietermaai 15, Willemstad, Curacao,
Netherlands Antilles ("Ferring").
Medi-Ject is the owner of rights with respect to a needle-free device for subcutaneous administration of
pharmaceutical drugs, the specifications for which are attached as Schedule A. Ferring wishes to have Medi-Ject
further develop such device for the administration of recombinant human growth hormone ("hGH") in accordance
with the specifications attached as Schedule B and, in connection therewith, to have exclusive rights with respect
to the use and sale of such modified device in the Territory (as hereafter defined) for the administration of hGH.
The parties agree as follows:
1) Definitions. As used in this Agreement, the following definitions will apply:
(a) "Affiliate: means any person or entity that directly, or indirectly through one or more intermediaries, controls,
or is controlled by, or is under common control with, another person or entity.
(b) "Health Regulatory Agencies" means health regulatory agencies in the various countries in the Territory and
the United States Food and Drug Administration.
(c) "Product" means a device for subcutaneous administration of hGH meeting the specifications set forth in
Schedules A and B with such modifications as may result from the development work to be carried out by Medi-
Ject pursuant to Section 2 hereof and as submitted to and approved by Health Regulatory Agencies, and
including any improvements thereon hereafter made by Medi-Ject or with respect to which Medi-Ject obtains
(d) "Regulatory Filings" means those registrations, applications and other filings with Health Regulatory Agencies
by Medi-Ject or its Affiliates, or by Ferring or its Affiliates, now or hereafter existing during the term of this
Agreement relating to the Product.
(e) "Technology" means any proprietary informa